Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023
This article describes the use of nirsevimab, a new drug approved in 2023, to prevent severe respiratory syncytial virus (RSV) disease in infants and young …
Ask aRCie
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
2024
· Centers for Disease Control and Prevention (CDC),
· Vanderbilt University,
· Seattle Children's Hospital,
· Baylor College of Medicine,
· University of Rochester
This study examines the effectiveness of nirsevimab, a monoclonal antibody, in preventing RSV-related hospitalizations in infants during their first RSV season. Conducted from October 2023 …
What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus
This review article discusses two preventive option for the prevention of RSV in infants: a maternal vaccine and a monoclonal antibody for infants. The FDA …
Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024
This article is about a study on RSV vaccination for pregnant women and their babies in the U.S. It describes how RSV is a common …
Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024
This report looks at a study on the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) illness and hospitalization among Alaska Native children in …